Kwality Pharmaceuticals

₹3,686As of Sun 8 Nov 2026, 12:00 UTC

NSE:KPLHealthcare

Country India

PE (Fwd) 59.92

TSR 10Y CAGR —

Div yield —

ROE —

Drug Manufacturers (Specialty & Generic)

Beta (5Y) 0.77

PE TTM 56.79

TSR TTM —

Mkt cap ₹40.10B

ROIC —

SE Grade™

Value

Quality

Moat

—

1Y Price

Reference

₹4,077

10.60%

(78.64%)

Price above Reference Value

TTM

FYE 31 Mar INR

FY2017

FY2018

FY2019

FY2020

FY2021

FY2022

FY2023

FY2024

FY2025

FY2026

FY2027E

Trend

10Y

Peers

5.031

Revenue₹B

—

4.562

2.510

3.072

3.702

5.031

5.040

2.48%

35.90

Revenue growth%

—

(44.97)

22.36

20.52

35.90

0.18

21.44

—

47.13

Gross margin%

—

55.03

54.75

48.56

49.16

47.13

47.12

49.16

19.97

Operating margin%

—

35.67

18.60

15.77

17.22

19.97

19.43

18.60

100

13.39

Net margin%

—

26.30

7.72

7.75

10.76

13.39

12.81

10.76

56.79

P/E ratio (avg)x

—

59.26

—

38.07

EV/EBITx

—

39.05

—

FCF yield (avg)%

—

FCF margin%

—

FCF / Net incomex

—

ROIC%

—

Return on equity%

—

Return on assets%

—

100

64.90

EPS₹

—

115.64

18.67

22.93

38.40

64.90

62.20

(13.45%)

—

69.02

EPS growth%

—

(83.86)

22.84

67.44

69.02

(4.16)

45.14

—

Bookvalue per sh₹

—

FCF per share₹

—

Dividend per sh₹

—

Div yield (avg)%

—

Payout ratio%

—

10.38

Shares (diluted)M

—

10.38

◌10.38

—

Buyback yield%

—

◌—

—

D/E ratiox

—

38.25

Enterprise value₹B

—

38.25

—

LT debt₹M

—

Peers (US$402.7M)

Cap (US$)

RPG Life Sciences…

450.8M

38.23x

Aarti Drugs Limited

433.3M

17.80x

Unichem Laboratories…

379.2M

10.52x

Kamada Ltd.

402.8M

19.69x

Capital

TTM

10Y

Leveragex

—

EBIT/Intx

9.157

7.754

Own earn%

—

Sh yield%

—

Owners

Insiders/Inst%

75.49

2.11

Short interest%

—

SBC / revenue%

—

Record

10Y

Profitable years

5/5

Revenue growth years

3/4

EPS growth years

3/4

Dividend streakyrs

Op margin range%

16–36

$1 testx

—

Incr. ROIC%

—

Kwality Pharmaceuticals Limited, together with its subsidiary, manufactures finished pharmaceutical formulations in India and internationally.

Growth vs revenue

Latest

Trend

4Y CAGR

Rel growth

Revenue

₹5.031B

2.48%

1.00×

Cost of revenue

₹2.660B

6.71%

1.18×

Operating expenses

₹1.366B

11.51%

1.40×

Revenue by region

No breakdown available

Reinvestment returns

n/m

Trend

Reinvestment rate

n/m

Return on capital

n/m

Spread over hurdle

n/m